Habte A. Yimer, MD

Articles by Habte A. Yimer, MD

Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed Myeloma

September 14th 2019

Habte A. Yimer, MD, of Texas Oncology, discusses a real-world study evaluating the long-term use of proteasome inhibition in patients with multiple myeloma, and transitioning from bortezomib (Velcade) to ixazomib (Ninlaro).

Latest Updated Articles

Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed Myeloma
Published: September 14th 2019 | Updated:

Habte A. Yimer, MD

Articles by Habte A. Yimer, MD

Dr. Yimer on Long-Term Proteasome Inhibition in Newly Diagnosed Myeloma

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma